Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery.
Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). This is a blinded study, so neither patients nor their doctors will know whether a patient gets tucatinib or placebo. All patients in the study will get T-DM1, a drug that is often used to treat this cancer.
Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills or placebo pills two times every day. Patients will get T-DM1 injections from the study site staff on the first day of every cycle.
This study is designed to evaluate the efficacy and safety of tucatinib in combination with T-DM1 in participants with unresectable locally-advanced or metastatic HER2+ breast cancer who have had prior treatment with a taxane and trastuzumab in any setting. Prior pertuzumab treatment is permitted, but not required. Participants will be randomized in a 1:1 manner to receive 21-day cycles of either tucatinib or placebo in combination with T-DM1.
While on study treatment, participants will be assessed for progression every 6 weeks for the first 24 weeks, and every 9 weeks thereafter, irrespective of dose holds or interruptions. Study treatment will continue until unacceptable toxicity, disease progression, withdrawal of consent, or study closure. After completion of study treatment and after occurrence of disease progression, participants in both arms of the study will continue to be followed for survival until study closure or withdrawal of consent.
Inclusion Criteria:
Histologically confirmed HER2+ breast carcinoma as determined by a sponsor-designated central laboratory
History of prior treatment with a taxane and trastuzumab in any setting, separately or in combination
Have progression of unresectable locally advanced/metastatic breast cancer after last systemic therapy, or be intolerant of last systemic therapy
Measurable or non-measurable disease assessable by RECIST v1.1
ECOG performance status score of 0 or 1
CNS Inclusion - Based on screening contrast brain magnetic resonance imaging (MRI), participants must have at least one of the following:
(a) No evidence of brain metastases
(b) Untreated brain metastases not needing immediate local therapy
(c) Previously treated brain metastases
Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy, provided that there is no clinical indication for immediate re-treatment with local therapy
Participants treated with CNS local therapy for newly identified lesions or previously treated and progressing lesions may be eligible to enroll if all of the following criteria are met:
(i) Time since SRS is at least 7 days prior to first dose of study treatment, time since WBRT is at least 14 days prior to first dose, or time since surgical resection is at least 28 days.
(ii) Other sites of evaluable disease are present
Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions
Exclusion Criteria:
Prior treatment with tucatinib, afatinib, trastuzumab deruxtecan (DS-8201a), or any other investigational anti-HER2, anti-EGFR, or HER2 TKI agent. Prior treatment with lapatinib or neratinib within 12 months of starting study treatment (except in cases where they were given for ≤21 days and was discontinued for reasons other than disease progression or severe toxicity). Prior treatment with pyrotinib for recurrent of mBC (except in cases where pyrotinib was given for ≤21 days and was discontinued for reasons other than disease progression or severe toxicity).
CNS Exclusion - Based on screening contrast brain magnetic resonance imaging (MRI), participants must not have any of the following:
Mobile, Alabama 36604, United States
Duarte, California 91010, United States
Los Angeles, California 90095, United States
Los Angeles, California 90095, United States
Orange, California 92868, United States
Sacramento, California 95814, United States
San Francisco, California 94158, United States
San Francisco, California 94518, United States
Aurora, Colorado 80045, United States
Aurora, Colorado 80045, United States
Aurora, Colorado 80045, United States
Lafayette, Colorado 80026, United States
Washington D.C., District of Columbia 20010, United States
Coral Gables, Florida 33146, United States
Tampa, Florida 33612, United States
Honolulu, Hawaii 96813, United States
Chicago, Illinois 60612, United States
Chicago, Illinois 60637, United States
New Lenox, Illinois 60451, United States
Orland Park, Illinois 60462, United States
Overland Park, Kansas 66211, United States
Overland Park, Kansas 66211, United States
Westwood, Kansas 66205, United States
Baltimore, Maryland 21201, United States
St Louis, Missouri 63110, United States
Charlotte, North Carolina 28203, United States
Charlotte, North Carolina 28204, United States
Philadelphia, Pennsylvania 19104, United States
Fort Worth, Texas 76104, United States
Fort Worth, Texas 76104, United States
Richardson, Texas 75080, United States
Richardson, Texas 75080, United States
Blacksburg, Virginia 24060, United States
Roanoke, Virginia 24014, United States
Salem, Virginia 24153, United States
Wytheville, Virginia 24382, United States
North Sydney, New South Wales 2060, Australia
Innsbruck, 6020, Austria
Nanjing, Jiangsu 210008, China
Hangzhou, Zhejiang 310002, China
Hangzhou, Zhejiang 310009, China
Offenbach/ Main, 63069, Germany
Offenbach/ Main, 63069, Germany
Offenbach/ Main, 63069, Germany
Offenbach/ Main, 63069, Germany
Petah Tikva, 4941492, Israel
Bologna, Emilia-Romagna 40138, Italy
Nagoya, Aichi-ken 464-0044, Japan
Kitaadachi-gun, Saitama 362-0806, Japan
Nagaizumi-cho, Shizuoka 411-8777, Japan
Chuo-ku, Tokyo 104-0045, Japan
J0nkoping, SE-551 85, Sweden
Birmingham, B15 2TH, United Kingdom